GYRE THERAPEUTICS, INC. (GYRE) Form 8-K — Jul 16, 2026
$GYREForm 8-KItems 5.02, 7.01, 9.01Filed Jul 16, 2026, 4:35 PM ET0001140361-26-028716Original filing
Gyre Therapeutics appointed three new members to its Board of Directors effective August 1, 2026, including current Chief Scientific Officer Dr. Yue Xiong, industry veteran Maxwell Kirkby, and Dr. Claire Weston. The appointments are intended to expand the board's expertise in global drug development, clinical operations, and cross-border biopharmaceutical operations as the company advances its pipeline targeting fibrosis and cancer.
Key figures
- Directors Appointed
- 3
- Vesting Period Years
- 3
- Stock Options Per New Director
- 40000
Price after filing
1 day: -7.8%7 days: -8.4%30 days: +1.8%
Close on the filing date to close N calendar days later (from $6.56). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.